Subscribe

News
Academy
Multimedia
Conferences
Publications
Partner Perspectives
Resources
Subscribe

Brand Insights - Thought Leadership | Paid Program | Deloitte

Are your Therapies Getting to the Patients that Need Them? It May be Time to Reframe your Market Access Strategy.

ByBrian Corvino, Brand Insights Contributor, Managing Director, Deloitte Consulting, LLP and Value, Access, Pricing Practice Leader,John Jaeger, Brand Insights Contributor, Managing Director, Deloitte Consulting LLP

Published: February 28th 2022 | Updated: March 15th 2022

Value/Access/Pricing: An essential enabler for delivering on the promise of oncology innovation

ByJoseph M. Coppola, Brand Insights Contributor, Managing Director, Commercial and Market Access Leader, Deloitte Consulting LLP,Brian Corvino, Brand Insights Contributor, Managing Director, Deloitte Consulting, LLP and Value, Access, Pricing Practice Leader

September 20th 2021

Pharmaceutical Product Pricing and Contracts Lifecycle Management: The Importance of Linking Strategy and Operations

ByJoseph M. Coppola, Brand Insights Contributor, Managing Director, Commercial and Market Access Leader, Deloitte Consulting LLP,Brian Corvino, Brand Insights Contributor, Managing Director, Deloitte Consulting, LLP and Value, Access, Pricing Practice Leader

June 12th 2021

The Pandemic Didn’t Hinder Drug Launches, but it Has Altered Sales Tactics

ByBrian Corvino, Brand Insights Contributor, Managing Director, Deloitte Consulting, LLP and Value, Access, Pricing Practice Leader,Candy Lurken, Brand Insights Contributor, Principal, Deloitte Consulting, LLP

May 11th 2021

Trending on PharmExec

Pharmaceutical Executive Daily: FDA Approves Hernexeos

The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms

FDA Approves Hernexeos Under National Priority Voucher Program

FDA Approves Dupixent as First Treatment for Allergic Fungal Rhinosinusitis in Adults and Children

What Does the Rollout of Trump Rx Reveal?